Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase NA 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 2Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 150pembrolizumab 132Magnetic Resonance Spectroscopy 120Cyclophosphamide 118Biopsy 106fludarabine 90Nivolumab 61Carboplatin 55Radiotherapy 49Cisplatin 49Gemcitabine 48venetoclax 43Paclitaxel 43Cetuximab 40fludarabine phosphate 39Ipilimumab 36Fluorouracil 35atezolizumab 34Bevacizumab 33durvalumab 30Radiation 30Oxaliplatin 29X-Rays 28Leucovorin 28Dexamethasone 28Azacitidine 27Irinotecan 26Cytarabine 26Radiosurgery 24Injections 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Glutamate Carboxypeptidase II × 90 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡